
Schematic structure of the bd-cytochrome. The bd-cytochrome is located in the bacterial inner (cytoplasmic) membrane. Next — an Escherichia coli bacterium (a bacterium encounters a molecule of hydrogen sulfide (H2S).
CREDIT
Vitaly Borisov
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe. The study is published in the Scientific Reports.
There is a prospect of a new type of antibiotics “turning off” the oxygen only to the harmful bacteria cells, not to human cells.
Scientists discovered how the E. coli bacterium can survive in the human gut – earlier the question how they breathe was a mystery to experts. Vitaliy Borisov, Senior Researcher, Doctor of Biological Sciences, Professor of the Russian Academy of Sciences, A.N. Belozersky Research Institute physical and chemical biology employee, the Lomonosov Moscow State University and one of the authors, explains that breathing E. coli uses special enzymes, which are absent in the human body. This means that the discovery of the scientists can contribute to the creation of new drugs, which will be detrimental to the bacteria without harming a human.
The energy for the vital activity of any organism comes from food, and is generated by the means of redox processes in the body. The food is converted into energy not directly but through intermediaries. First, the complex molecules are decomposed into simpler: proteins are decomposed into amino acids, fats – to fatty acids, carbohydrates – to monosaccharides. Oxidation of simpler molecules releases energy, which all is contained in the electrons.
The electrons passes to the respiratory chain with the so-called reducing equivalents (electron-carrying compound). They are NADH (nicotinamide adenine dinucleotide) and ubiquinol, also known as coenzyme Q. These two basic reducing equivalents fully cope with the processing of food: NADH is a water-soluble compound and ubiquinol is fat-soluble. Membranous enzymes accept electrons from reducing equivalents and transfer them to molecular oxygen.
The terminal cytochrome oxidase is the main membrane enzyme responsible for the human mitochondrial respiration and was thought to be used for the breath of E. coli as well. The scheme of oxidases action is simple: transferring electrons to molecular oxygen, reducing equivalents are oxidized again, and as a result “the energy currency” of the cell – the proton-moving force is generated.
‘If you stop breathing, you die just because oxygen does not flow to the oxidase, and it does not produce energy,’ said Vitaly Borisov.
The Escherichia coli bacterium lives in the gastrointestinal tract, where a lot of hydrogen sulfide is produced, which attenuates mitochondrial respiration. Free hydrogen sulfide inhibits cytochrome oxidase work. Its concentration exceeds several hundred times the minimum concentration required for substantial blocking of this enzyme. Hence, it seems that the E. coli bacterium cannot “breathe”, but despite that the bacteria somehow survive in the intestine. The researchers assumed that the breath in the presence of hydrogen sulfide is still possible, but due to other oxidase. The fact is that the breath in people and bacteria occur in different ways. Each cell in our body “breathes” due to the work of only the cytochrome-c oxidase, others we have not. However, the E. coli bacteria has two types of oxidase: bo-type cytochrome oxidase (analogue of “human” cytochrome-c oxidase) and completely different bd-type cytochromes.
‘Our hypothesis was that the bd-type oxidase (bd-I and bd-II) are more resistant to the hydrogen sulfide inhibition than the bo-type cytochrome oxidase,’ commented Vitaly Borisov.
To test this hypothesis scientists needed to learn how the sulfide presence in the environment affects the growth of the E. coli bacteria cells, which have only one terminal oxidase (bd-I, bd-II or bo) in the respiratory chain. a variety of biochemical, biophysical and microbiological methods and approaches were applied, as well as the method of the intended mutagenesis.
The hypothesis was fully confirmed.
‘Bo-oxidase’s activity is completely inhibited by the hydrogen sulfide, while the work of the bd-oxidases remains untouched by the H2S. Thus, in order to successfully produce the main types of “the energy currency” under a high concentration of hydrogen sulfide, the intestinal microflora inhabitants should use a unique type of terminal oxidases, which is missing in the cells of humans and animals,’ said Vitaly Borisov.
The discovery could be used in the future to develop medicines that regulate the intestinal microflora and relieving it from harmful bacteria. As human cells do not contain the bd-type oxidase, the question of the ability to combat disease-causing bacteria without causing harm to the human body becomes relevant. For example, the bacterium causing tuberculosis, which’s primarily membrane enzyme is also a bd-type oxidase, quickly gaining resistance to classical antibiotics. Through this study there is a prospect of a new type of antibiotics “turning off” the oxygen only to the harmful bacteria cells, not to human cells.
Learn more: Revolutionary Antibiotics that Will Save the World?
The Latest on: Revolutionary Antibiotics
via Google News
The Latest on: Revolutionary Antibiotics
- Chris Hedges: The Age of Social Murderon March 2, 2021 at 10:54 pm
This is the largest crime against humanity ever committed. It is being committed in front of us. And, with few exceptions, we are willfully being herded like sheep to the slaughter. By Chris Hedges ...
- FMI Highlights Accelerating Sales of Antibiotics in the Corneal Ulcer Treatment Marketspaceon February 25, 2021 at 10:17 pm
FMI Highlights Accelerating Sales of Antibiotics in the Corneal Ulcer Treatment Marketspace Corneal ulcer is among the main sources of blindness, especially in developing regions, with factors ...
- Beyond Meat® Reports Fourth Quarter and Full Year 2020 Financial Resultson February 25, 2021 at 1:09 pm
Beyond Meat, Inc. (NASDAQ: BYND) (“Beyond Meat” or “the Company”), a leader in plant-based meat, today reported financial results for its fourth quarter and full year ended December 31, 2020. Fourth ...
- Feed Phytogenics Market 2020: Drivers, Restraints, Opportunities, Threats, Trends, Applications, Growth Analysis and Forecast To 2025on February 25, 2021 at 6:56 am
The global Feed Phytogenics market was valued at USD 548.1 million in 2016 and is projected to reach USD 1007.7 million by 2025, growing at a CAGR of 7.1% from 2017 to 2025. Phytogenics are additives ...
- BurgerFi’s On-trend Brand Has Appeal in Saudi Arabiaon February 24, 2021 at 7:11 am
A new Saudi Arabian restaurant group is bringing fast-casual chain BurgerFi to the country, where consumer demand for clean ingredients is growing. Newly public, BurgerFi is also poised for more ...
- 'Supercharger' to revive mainstay antibiotic in global fight against antibiotic resistanceon February 19, 2021 at 9:56 pm
MELBOURNE, Australia, Feb. 11, 2021 /PRNewswire/ -- SuperTrans Medical (STM), a biopharmaceutical company developing novel antibiotics that target difficult-to-treat, multi-drug resistant bacteria, ...
- AI-based mobile application to fight antibiotic resistanceon February 19, 2021 at 2:25 am
Antimicrobial resistance is a major global health threat and its development is promoted by antibiotic misuse. Here, the authors present an offline smartphone application for automated and ...
- Plant-Based Meat Analog, Scope and Futureon February 19, 2021 at 12:26 am
Plant-Based Meat Analog, Scope and Future By Asim Syed, Director, Food Applications R&D, Brenntag North America - The global food industry is going through a major life-changing event with the ...
- 'Supercharger' to revive mainstay antibiotic in global fight against antibiotic resistanceon February 11, 2021 at 9:12 am
MELBOURNE, Australia, Feb. 11, 2021 /PRNewswire/ -- SuperTrans Medical (STM), a biopharmaceutical company developing novel antibiotics that target difficult-to-treat, multi-drug resistant bacteria ...
- Global Antibiotics Market By Action Mechanism, By Drug Class, By Region, Industry Analysis and Forecast, 2020 - 2026on February 10, 2021 at 4:45 am
Oct-2017: Roche partnered with Warp Drive Bio, a subsidiary of Revolution Medicines. The partnership focused on the development of new classes of antibiotics against multidrug-resistant bacterial ...
via Bing News